HHS, DOD award $481M for point-of-care COVID-19 test, announce vaccine manufacturer partnership
The Department of Health and Human Services and the Department of Defense yesterday awarded $481 million to Cue Health Inc. to expand production of a point-of-care COVID-19 molecular test with capabilities to produce results in 20 minutes.
Cue said the highly sensitive test uses a nasal swab sample to detect RNA of SARS-CoV-2, the virus that causes COVID-19. HHS said the partnership allows Cue to increase production to 100,000 test kits per day by March 2021.
Also yesterday, HHS and DOD announced a separate, $31 million agreement with Cytiva to expand the company’s capacity to produce items essential to the production of COVID-19 vaccines such as liquid and dry powder cell culture media, cell culture buffers, mixer bags, and bioreactors.
Related News Articles
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…